Search Result
Results for "
CD4+T+cells
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-148808
-
|
RXC007
|
ROCK
|
Cancer
|
|
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma [4].
|
-
-
- HY-P1745
-
|
Insulin B chain (9-23)
|
MHC
Insulin Receptor
IFNAR
|
Inflammation/Immunology
|
|
InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .
|
-
-
- HY-15898
-
Y-320
5 Publications Verification
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Y-320 is a potent, orally active phenylpyrazoleanilide immunomodulator. Y-320 inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM. Y-320 enhances TP53, DMD, and COL17A1 PTC readthrough by G418 and increases cellular protein levels and protein synthesis. Y-320 concomitants use of with a low dose of Paclitaxel (HY-B0015) significantly sensitized multidrug resistance (MDR) tumors by inducing G2/M phase arrest and apoptosis. Y-320 can be used for research of rheumatoid arthritis (RA) and cancer .
|
-
-
- HY-139780
-
|
|
ROR
|
Inflammation/Immunology
|
|
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions .
|
-
-
- HY-108136A
-
|
BIM-X hydrochloride; Ro31-8425 hydrochloride
|
PKC
CDK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Bisindolylmaleimide X hydrochloride(Ro 31-8425 hydrochloride, BIM-X hydrochloride) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X hydrochloride inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X hydrochloride inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X hydrochloride can be used for research on the immune system and cardiovascular diseases .
|
-
-
- HY-165613
-
|
Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine
|
Toll-like Receptor (TLR)
Influenza Virus
NF-κB
|
Infection
Inflammation/Immunology
|
|
Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection [4].
|
-
-
- HY-P991424
-
|
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-164426
-
HEI3090
1 Publications Verification
|
P2X Receptor
Interleukin Related
IFNAR
|
Inflammation/Immunology
Cancer
|
|
HEI3090 is a P2X7R activator. HEI3090 stimulates dendritic cells expressing P2X7R to produce IL-18, which subsequently promotes Natural Killer cells and CD4 T cells within tumors to produce IFN-γ, leading to a sustained antitumor response. HEI3090 can be used to enhance the efficacy of αPD-1 therapy in non-small cell lung cancer (NSCLC) .
|
-
-
- HY-148511
-
|
CMP-001
|
Toll-like Receptor (TLR)
IFNAR
PD-1/PD-L1
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer [4].
|
-
-
- HY-P1997
-
|
Desferrichrome; DFC; N-Desferriferrichrome
|
Biochemical Assay Reagents
|
Others
|
|
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.
|
-
-
- HY-160267
-
|
|
HIV
DNA/RNA Synthesis
|
Infection
Neurological Disease
Cancer
|
|
iPAF1C is a inhibitor of the polymerase-associated factor 1 complex (PAF1C) with specific targeting to the PAF1 binding groove of CTR9 (a key subunit of PAF1C). iPAF1C disrupts PAF1C assembly by interfering with the PAF1-CTR9 interaction. iPAF1C selectively impairs BRD4-mediated recruitment of PAF1 to chromatin at hypoxia-responsive genes and inhibits RNA polymerase II (RNAPII) pause release. iPAF1C increases the population of HIV-1 NL4.3 Nef-IRES-GFP infected primary human CD4 +T cells in a dose-dependent manner. PAF1C can be used for the study of infection and diseases associated with abnormal hypoxic adaptation (e.g., cancers, neurological disorders) .
|
-
-
- HY-105037A
-
|
IPP-201101 TFA
|
Autophagy
|
Inflammation/Immunology
|
|
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [4].
|
-
-
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
-
- HY-105037
-
|
IPP-201101
|
Autophagy
|
Inflammation/Immunology
|
|
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [4].
|
-
-
- HY-B0757
-
|
|
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Vitamin E nicotinate is the derivative of Vitamin E. Vitamin E nicotinate exhibits antioxidant activity and prevents lipid peroxidation. Vitamin E nicotinate upregulates levels of CD4+ T cells and IL-2, exhibits immunomodulatory activity. Vitamin E nicotinate exhibits antiplatelet and antihypertensive activities, that can be used in atherosclerosis and thrombosis ressearch .
|
-
-
- HY-15440R
-
|
BMS-626529 (Standard)
|
HIV
Reference Standards
|
Infection
|
|
Temsavir (Standard) is the analytical standard of Temsavir. This product is intended for research and analytical applications. Temsavir (BMS-626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.
|
-
-
- HY-131675
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
CH-100 is an immunomodulatory agent targeting T-cell activation and inflammatory mediator production. CH-100 demonstrates anti-inflammatory and hepatoprotective effects by reducing TNF-α secretion, suppressing CD4+ T-cell proliferation, and lowering endotoxin levels in alcohol-fed rats. CH-100 is promising for research of alcoholic liver disease and T-cell-mediated hepatitis .
|
-
-
- HY-12926
-
|
|
HIV
HDAC
DNA/RNA Synthesis
|
Infection
|
|
ST7612AA1 is a histone deacetylase (HDAC) inhibitor that controls chromatin condensation and DNA transcription by removing acetyl groups from histones. ST7612AA1 is also a potent HIV reactivation inducer, and its reactivation activity is exerted without activating or proliferating CD4+T cells, and can be used in the study of HIV reactivation strategies and elimination of viral reservoirs .
|
-
-
- HY-P11122
-
|
|
IFNAR
Interleukin Related
|
Inflammation/Immunology
|
MSP-1 P2 is a synthetic peptide of merozoite surface protein-1 (MSP-1). MSP-1 P2 stimulates umbilical cord blood lymphocytes to produce IFN-γ and IL-13, and this immune response is primarily mediated by CD4+ T cells. MSP-1 P2 can be used as a specific antigen stimulus to detect T cell responses and cytokine levels .
|
-
-
- HY-P10382
-
|
|
MHC
|
Inflammation/Immunology
|
|
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .
|
-
-
- HY-15440BR
-
|
BMS-663068 Tris (Standard)
|
HIV
Reference Standards
|
Infection
|
|
Fostemsavir Tris (Standard) is the analytical standard of Fostemsavir Tris. This product is intended for research and analytical applications. Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl proagent of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells.
|
-
-
- HY-P10826
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .
|
-
-
- HY-119347R
-
|
|
Reference Standards
IFNAR
STAT
|
Inflammation/Immunology
Cancer
|
|
Cirsilineol (Standard) is the analytical standard of Cirsilineol. This product is intended for research and analytical applications. Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice .
|
-
-
- HY-15091
-
|
LF-150195
|
Endogenous Metabolite
|
Neurological Disease
|
|
Anisperimus (LF-150195) is an immunosuppressant with the activity of enhancing activation-induced T cell death. Anisperimus enhances the sensitivity of T cells to anti-CD95 antibodies and other inducers by promoting the activation of caspase-8 and caspase-10 at the level of the death-inducing signaling complex (DISC). Anisperimus also promotes the development of Foxp3-expressing regulatory CD4 T cells, thereby preventing central nervous system autoimmunity .
|
-
-
- HY-173052
-
|
|
CXCR
|
Inflammation/Immunology
|
|
SLW131 (Compound 10) is the antagonist for CCR7 with a good affinity of Ki of 9.85 nM. SLW131 inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM, inhibits β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 inhibits CCL19-induced cell morphological changes in primary BMDCs, and CCR7-mediated migration in mouse CD4+ T cell .
|
-
-
- HY-144746
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases .
|
-
-
- HY-176280
-
|
|
SARS-CoV
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
|
Infection
|
|
SARS-CoV-2-IN-115 (Compound 3e) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-115 has potent antiviral activity against SARS-CoV-2 in infected Calu-3 cells (EC50: 1.7 μM). SARS-CoV-2-IN-115 effectively inhibits the activity of human dihydroorotate dehydrogenase (HsDHODH) (IC50: 1.5 μM). SARS-CoV-2-IN-115 preserves immune response without antiproliferative effects on CD4 T cells .
|
-
-
- HY-177277
-
|
|
PI3K
|
Inflammation/Immunology
|
|
HM5023507 is an orally active and selective PI3Kδ/γ inhibitor with IC50s of 4 and 5 μM for PI3Kδ and PI3Kγ over PI3Kβ and PI3Kα. HM5023507 attenuates the PI3Kδ/γ signaling in human basophils. HM5023507 also attenuates the activation and function of human B and T cells and cytokine and IgG production during cocultures, and Th17 differentiation of CD4 T cells. HM5023507 inhibited semiestablished collagen-induced arthritic inflammation in the rat models. HM5023507 can be used for inflammatory diseases like rheumatoid arthritis research .
|
-
-
- HY-108136
-
|
BIM-X; Ro31-8425
|
PKC
CDK
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Bisindolylmaleimide X (Ro 31-8425, BIM-X) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X can be used for research on the immune system and cardiovascular diseases .
|
-
-
- HY-P991892A
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
|
-
-
- HY-P991762
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD4 Antibody (W3/25) reacts with rat CD4. Anti-Rat CD4 Antibody (W3/25) inhibits CD4+ T cell activation by downregulating the CD4 molecule on the surface of lymphocytes. Anti-Rat CD4 Antibody (W3/25) inhibits antigen-induced T cell proliferation and IL2 production in MLR experiments. Anti-Rat CD4 Antibody (W3/25) can be used for the study of experimental allergic encephalomyelitis (EAE). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) [4].
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1745
-
|
Insulin B chain (9-23)
|
MHC
Insulin Receptor
IFNAR
|
Inflammation/Immunology
|
|
InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .
|
-
- HY-P1997
-
|
Desferrichrome; DFC; N-Desferriferrichrome
|
Biochemical Assay Reagents
|
Others
|
|
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.
|
-
- HY-105037A
-
|
IPP-201101 TFA
|
Autophagy
|
Inflammation/Immunology
|
|
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [4].
|
-
- HY-P5425
-
|
|
Peptides
|
Others
|
|
Tetanus Toxin (830–844) is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population)
|
-
- HY-105037
-
|
IPP-201101
|
Autophagy
|
Inflammation/Immunology
|
|
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [4].
|
-
- HY-P10512
-
|
|
Peptides
|
Others
|
|
BDC2.5 mimotope is a potent antigen-mimicking peptide that can activate CD4+ T cell populations that have the same antigen recognition properties as BDC2.5 cells. BDC2.5 mimotope can be used to study the prevention or treatment of type 1 diabetes by targeting specific T cell populations .
|
-
- HY-P11122
-
|
|
IFNAR
Interleukin Related
|
Inflammation/Immunology
|
MSP-1 P2 is a synthetic peptide of merozoite surface protein-1 (MSP-1). MSP-1 P2 stimulates umbilical cord blood lymphocytes to produce IFN-γ and IL-13, and this immune response is primarily mediated by CD4+ T cells. MSP-1 P2 can be used as a specific antigen stimulus to detect T cell responses and cytokine levels .
|
-
- HY-P10382
-
|
|
MHC
|
Inflammation/Immunology
|
|
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .
|
-
- HY-P10826
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .
|
-
- HY-K0352
-
1 Publications Verification
|
|
MCE Human CD4+ T Cells Negative Selection Kit is designed to isolate CD4+ T cells from human peripheral blood mononuclear cells (PBMCs).
|
-
- HY-K0307
-
|
|
|
MCE Mouse CD4+ T Cells Negative Selection Kit is designed for the isolation of CD4+ T cells from single cell suspensions of mouse spleen cells and lymph nodes.
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P991424
-
|
|
Interleukin Related
STAT
|
Inflammation/Immunology
|
|
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
(5)
-
- HY-P991892A
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer .
|
-
(5)
-
- HY-P991762
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD4 Antibody (W3/25) reacts with rat CD4. Anti-Rat CD4 Antibody (W3/25) inhibits CD4+ T cell activation by downregulating the CD4 molecule on the surface of lymphocytes. Anti-Rat CD4 Antibody (W3/25) inhibits antigen-induced T cell proliferation and IL2 production in MLR experiments. Anti-Rat CD4 Antibody (W3/25) can be used for the study of experimental allergic encephalomyelitis (EAE). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) [4].
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
|
Classification |
-
- HY-148511
-
|
CMP-001
|
|
CpG ODNs
|
|
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer [4].
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: